AI Insight
Grail's landmark Galleri trial, involving 140,000 UK residents, failed to meet its primary endpoint of reducing late-stage cancer diagnoses. The randomized controlled trial compared usual care combined with multicancer detection blood testing against usual care alone. This represents a significant setback for the development of viable multicancer detection tests, which aim to identify multiple cancer types through a single blood draw.
Why it matters
The failure of this large-scale trial raises important questions about the clinical utility of multicancer detection tests as a screening strategy. This outcome may significantly impact investment, regulatory approval pathways, and clinical implementation timelines for similar diagnostic technologies that have been positioned as transformative tools in early cancer detection.
Understand the Science
A single blood test that can identify most cancers remains the aspirational goal of cancer screening. The US biotechnology company Grail has been closest to developing a viable multicancer detection test. In June, 2026, the high hopes of many were dashed at the annual American Society of Clinical Oncology (ASCO) scientific meeting: Grail’s landmark Galleri trial, which randomly assigned 140 000 UK residents to usual care plus multicancer detection testing versus usual care alone, failed to meet its primary endpoint—a reduction in late-stage cancers.
Source: [Correspondence] Multicancer detection tests: holy grail or cautionary tale?